The Cochrane Airways Group has determined that use of a fixed dose inhaler containing both a steroid and beta₂‐agonist as required instead of short‐acting beta agonist (SABA) monotherapy as required is clinically effective in adults and adolescents with mild asthma. In a review of the evidence it found fast-acting beta agonist/inhaled corticosteroid (FABA/ICS) reduced exacerbations ...
Cochrane backs fixed-dose combination inhaler for mild asthma
By Mardi Chapman
24 May 2021